The Prescriber Opioid Risk Reduction Strategies (PORRS) Study

处方者阿片类药物风险降低策略 (PORRS) 研究

基本信息

  • 批准号:
    8468562
  • 负责人:
  • 金额:
    $ 1.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-05 至 2015-08-31
  • 项目状态:
    已结题

项目摘要

The Prescriber Opioid Risk Reduction Strategies (PORRS) Study Abstract Opioid misuse, abuse and addiction are growing public health problems. Prescription opioid-related overdoses tripled from 1999-2009 (Warner et al 2009) and emergency department admissions for misuse and abuse of prescription drugs doubled from 2004-2009 with almost half (47.9%) of these admissions involving prescription opioids (SAMSHA 2011). Primary concerns focus on adolescent and adult populations aged 15-64. Opioids of greatest concern (e.g., oxycodone, hydrocodone, methadone, morphine, codeine) are found in single- entity and combination drug products categorized as Schedule II and Schedule III controlled substances. Managing these products and the risk they present is the focus of diverse public and private efforts. Major public initiatives include state-level Prescription Drug Monitoring Programs (PDMPs) that have been supported by the U.S. Department of Justice for over a decade and the more recent U.S. Food and Drug Administration (FDA)-led Risk Evaluation and Management Strategies (REMS) program that addresses extended-release and long-acting opioids. Public and private health insurers have implemented policies that limit opioid prescribing and increasingly provide prescribers with real-time, patient-specific information regarding prescribing concerns. At the clinic- or provider-level, research literature supports clinical practices such as brief screening to identify problems with opioid abuse and treatment contracts to address them. Each of these initiatives provides a strategy that prescribers can use to identify and/or reduce opioid risk through patient assessment, education, or monitoring. But to what extent do prescribers know about these strategies and how do different prescribers employ them in day-to-day practice? To what extent are these strategies viewed as effective and what do prescribers feel would increase their effectiveness? Despite the importance of these strategies for opioid risk reduction, little is known about prescriber perspectives on any one of them and essentially nothing is known about how prescribers see them comparatively or use them in tandem. This study will address these questions and, based on answers to them, develop recommendations and practical tools to enhance use of opioid risk reduction strategies. Focusing on prescribers in Wisconsin, a state- wide survey of selected generalist and specialist physicians will be conducted to describe their use of and perspectives on specific strategies, alone and in combination (Specific Aim 1). Survey data will be supplemented with information related to respondent practice patterns then analyzed to identify factors associated with use and perspectives on specific strategies (Specific Aim 2). After reviewing these results and respondents' suggestions for improving effectiveness of opioid risk reduction strategies, the project's advisory group will develop and disseminate improvement recommendations; with advisory group assistance, project staff will develop practical tools to assist prescribers with using specific opioid risk reduction strategies (Specific Aim 3).
处方阿片类药物风险降低策略(PORRS)研究

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEANINE K. MOUNT其他文献

JEANINE K. MOUNT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEANINE K. MOUNT', 18)}}的其他基金

The Prescriber Opioid Risk Reduction Strategies (PORRS) Study
处方者阿片类药物风险降低策略 (PORRS) 研究
  • 批准号:
    8540398
  • 财政年份:
    2012
  • 资助金额:
    $ 1.39万
  • 项目类别:
Pro-Active Pharmacy-Based Vaccination Study: A Multi-State Intervention
基于药房的主动疫苗接种研究:多州干预
  • 批准号:
    7089433
  • 财政年份:
    2005
  • 资助金额:
    $ 1.39万
  • 项目类别:
Pro-Active Pharmacy-Based Vaccination Study: A Multi-State Intervention
基于药房的主动疫苗接种研究:多州干预
  • 批准号:
    7121250
  • 财政年份:
    2005
  • 资助金额:
    $ 1.39万
  • 项目类别:

相似海外基金

Pain, Multimorbidity, Opioid-Drug Interactions and Risk for Opioid Use Disorder or Overdose in Older Adults
老年人的疼痛、多重发病、阿片类药物相互作用以及阿片类药物使用障碍或过量的风险
  • 批准号:
    10659436
  • 财政年份:
    2023
  • 资助金额:
    $ 1.39万
  • 项目类别:
Novel application of pharmaceutical AMD3100 to reduce risk in opioid use disorder: investigations of a causal relationship between CXCR4 expression and addiction vulnerability
药物 AMD3100 降低阿片类药物使用障碍风险的新应用:CXCR4 表达与成瘾脆弱性之间因果关系的研究
  • 批准号:
    10678062
  • 财政年份:
    2023
  • 资助金额:
    $ 1.39万
  • 项目类别:
Opioid Use and Acute Suicide Risk: The Real-Time Influence of Trauma Context"
阿片类药物的使用和急性自杀风险:创伤背景的实时影响”
  • 批准号:
    10674342
  • 财政年份:
    2023
  • 资助金额:
    $ 1.39万
  • 项目类别:
Comparative Risk of Oral Complications Associated with Medications for Opioid Use Disorder: A Mixed-Methods Approach
与阿片类药物使用障碍药物相关的口腔并发症的风险比较:混合方法
  • 批准号:
    10765049
  • 财政年份:
    2023
  • 资助金额:
    $ 1.39万
  • 项目类别:
Real time relapse risk scoring for Opioid Use Disorder (OUD) from clinical trial datasets
根据临床试验数据集对阿片类药物使用障碍 (OUD) 进行实时复发风险评分
  • 批准号:
    10585452
  • 财政年份:
    2023
  • 资助金额:
    $ 1.39万
  • 项目类别:
Engagement in opioid agonist therapy and risk for repeat overdose in people with and without HIV who experienced a nonfatal opioid overdose: providing insight to improve clinical care
经历过非致命性阿片类药物过量的艾滋病毒感染者和非艾滋病毒患者接受阿片类激动剂治疗以及重复用药过量的风险:提供见解以改善临床护理
  • 批准号:
    484635
  • 财政年份:
    2023
  • 资助金额:
    $ 1.39万
  • 项目类别:
    Fellowship Programs
A mechanistic investigation of risk factors for opioid use disorder: Examining hippocampal-based context-dependent learning and memory associated with adverse childhood experiences
阿片类药物使用障碍危险因素的机制研究:检查与不良童年经历相关的基于海马的情境依赖学习和记忆
  • 批准号:
    10707793
  • 财政年份:
    2023
  • 资助金额:
    $ 1.39万
  • 项目类别:
Developing a Clinical Decision Support Tool that Assesses Risk of Opioid Use Disorder Using Natural Language Processing, Machine Learning, and Social Determinants of Health from Clinical Notes
开发一种临床决策支持工具,利用自然语言处理、机器学习和临床记录中的健康社会决定因素来评估阿片类药物使用障碍的风险
  • 批准号:
    10352097
  • 财政年份:
    2022
  • 资助金额:
    $ 1.39万
  • 项目类别:
Real-world complexities in opioid use disorder treatment: understanding family comorbidity, high-risk medication use, and costs related to treatment adherence and health outcomes
阿片类药物使用障碍治疗的现实复杂性:了解家庭合并症、高风险药物使用以及与治疗依从性和健康结果相关的成本
  • 批准号:
    10449784
  • 财政年份:
    2022
  • 资助金额:
    $ 1.39万
  • 项目类别:
Examination of evolving opioid misuse and overdose risk among American Indians
检查美洲印第安人中不断变化的阿片类药物滥用和过量风险
  • 批准号:
    10438466
  • 财政年份:
    2022
  • 资助金额:
    $ 1.39万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了